Newborn Hearing Screenings in Human Immunodeficiency Virus-Exposed Uninfected Infants

P Torre Rd, B Zeldow, T J Yao, H J Hoffman, G K Siberry, M U Purswani, T Frederick, S A Spector, P L Williams, P Torre Rd, B Zeldow, T J Yao, H J Hoffman, G K Siberry, M U Purswani, T Frederick, S A Spector, P L Williams

Abstract

Perinatal HIV infection and congenital cytomegalovirus (CMV) infection may increase the risk for hearing loss. We examined 1,435 infants enrolled in the Surveillance Monitoring of ART Toxicities (SMARTT) study of the Pediatric HIV/AIDS Cohort Study (PHACS) network, a prospective study of the safety of in utero antiretroviral (ARV) exposures. We determined the proportion of perinatally HIV-exposed uninfected (HEU) newborns who were referred for additional hearing testing, and evaluated the association between in utero ARV exposures and newborn hearing screening results. Using a nested case-control design, we also examined congenital CMV infection in infants with and without screening referral. Congenital CMV infection was determined based on CMV DNA detection using a nested PCR assay in peripheral blood mononuclear cells obtained within 14 days of birth. Among the 1,435 infants (70% black, 31% Hispanic, 51% male), 45 (3.1%) did not pass the hearing screen and were referred for further hearing testing. Based on exact logistic regression models controlling for maternal use of tobacco and ototoxic medications, first trimester exposure to Tenofovir was associated with lower odds of a newborn hearing screening referral [adjusted odds ratio (aOR) = 0.41, 95% confidence interval (CI): 0.14-1.00]. Exposure to Atazanavir was linked to higher odds of newborn screening referral, although not attaining significance [aOR = 1.84, 95% CI: 0.92-3.56]. Maternal ARV use may have varying effects on newborn hearing screenings. These results highlight the importance for audiologists to be knowledgeable of in utero ARV exposures in HEU children because of the possibility of higher referrals in these children.

Keywords: Cytomegalovirus; Hearing; Human Immunodeficiency Virus; In Utero Antiretroviral Exposure; Newborn.

Figures

Figure 1
Figure 1
Estimated associations between maternal ARV exposures and newborn hearing screening referral (or failed screening) using exact adjusted logistic regression, separated by any exposure (1a) 1st trimester exposure (1b) Associations were adjusted for maternal use of ototoxic medications and in utero tobacco exposure.

References

    1. Early identification of hearing impairment in infants and young children. NIH Consensus Statement. 1993;11:1–24.
    1. NIH Fact Sheet. Newborn Hearing Screening. Updated Oct 2010.
    1. Joint Committee on Infant Hearing. Year 2007 Position Statement: Principles and Guidelines for early hearing detection and intervention programs. Pediatrics. 2007;120:898–921. doi: 10.1542/peds.2007-2333.
    1. Yoshinaga-Itano C, Apuzzo ML. Identification of hearing loss after age 18 months is not early enough. Am Ann Deaf. 1998;143(5):380–7.
    1. Yoshinaga-Itano C, Sedey AL, Coulter DK, Mehl AL. Language of early- and later-identified children with hearing loss. Pediatrics. 1998;102(5):1161–71.
    1. Dalzell L, Orlando M, MacDonald M, Berg A, Bradley M, Cacace A, et al. The New York State universal newborn hearing screening demonstration project: ages of hearing loss identification, hearing aid fitting, and enrollment in early intervention. Ear Hear. 2000;21(2):118–30.
    1. Vohr BR, Carty LM, Moore PE, Letourneau K. The Rhode Island Hearing Assessment Program: experience with statewide hearing screening (1993-1996) J Pediatr. 1998;133(3):353–7.
    1. Torre P, 3rd, Zeldow B, Hoffman HJ, Buchanan A, Siberry GK, Rice M, et al. Hearing loss in perinatally HIV-infected and HIV-exposed but uninfected children and adolescents. Pediatr Infect Dis J. 2012;31(8):835–41. doi: 10.1097/INF.0b013e31825b9524.
    1. Olusanya BO, Afe AJ, Onyia NO. Infants with HIV-infected mothers in a universal newborn hearing screening programme in Lagos, Nigeria. Acta Paediatr. 2009;98(8):1288–93. doi: 10.1111/j.1651-2227.2009.01337.x.
    1. Manfredi AK, Zuanetti PA, Mishima F, Granzotti RB. Newborn hearing screening in infants born to HIV-seropositive mothers. J Soc Bras Fonoaudiol. 2011;23(4):376–80.
    1. Barbi M, Binda S, Caroppo S, Ambrosetti U, Corbetta C, Sergi P. A wider role for congenital cytomegalovirus infection in sensorineural hearing loss. Pediatr Infect Dis J. 2003;22(1):39–42.
    1. Dahle AJ, Fowler KB, Wright JD, Boppana SB, Britt WJ, Pass RF. Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. J Am Acad Audiol. 2000;11(5):283–90.
    1. Fowler KB, Boppanna SB. Congenital cytomegalovirus (CMV) infection and hearing deficit. J Clin Virol. 2006;35(2):226–31.
    1. Yamamoto AY, Mussi-Pinhata MM, Isaac Mde L, Amaral FR, Carvalheiro CG, Aragon DC, et al. Congenital cytomegalovirus infection as a cause of sensorineural hearing loss in a highly immune population. Pediatr Infect Dis J. 2011;30(12):1043–6. doi: 10.1097/INF.0b013e31822d9640.
    1. Doyle M, Atkins JT, Rivera-Matos IR. Congenital cytomegalovirus infection in infants infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 1996;15(12):1102–6.
    1. Mussi-Pinhata MM, Yamamoto AY, Figueiredo LT, Cervi MC, Duarte G. Congenital and perinatal cytomegalovirus infection in infants born to mothers infected with human immunodeficiency virus. J Pediatr. 1998;132(2):285–90.
    1. Guibert G, Warszawski J, Le Chenadec J, Blanche S, Benmebarek Y, Mandelbrot L, et al. Decreased risk of congenital cytomegalovirus infection in children born to HIV-1-infected mothers in the era of highly active antiretroviral therapy. Clin Infect Dis. 2009;48(11):1516–25. doi: 10.1086/598934.
    1. Williams PL, Seage GR, 3rd, Van Dyke RB, Siberry GK, Griner R, Tassiopoulos K, et al. A trigger-based design for evaluating the safety of in utero antiretroviral exposure in uninfected children of human immunodeficiency virus-infected mothers. Am J Epidemiol. 2012;175(9):950–61. doi: 10.1093/aje/kwr401.
    1. Tassiopoulos K, Read JS, Brogly S, Rich K, Lester B, Spector SA, et al. Substance use in HIV-infected women during pregnancy: self-report versus meconium analysis. AIDS Behav. 2010;14(6):1269–78. doi: 10.1007/s10461-010-9705-0.
    1. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol. 1991;72(Pt 9):2059–64.
    1. Rice ML, Zeldow B, Siberry GK, Purswani M, Malee K, Hoffman HJ, et al. Evaluation of risk for late language emergence after in utero antiretroviral drug exposure in HIV-exposed uninfected infants. Pediatr Infect Dis J. 2013;32(10):e406–13. doi: 10.1097/INF.0b013e31829b80ee.
    1. King G, Zeng L. Logistic regression in rare events data. Polit anal. 2001;9:137–163.
    1. Frederick T, Homans J, Spencer L, Kramer F, Stek A, Operskalski E, et al. The effect of Prenatal Highly Active Antiretroviral Therapy on the Transmission of Congenital and Perinatal/Early Postnatal Cytomegalovirus Among HIV-Infected and HIV-Exposed Infants. Clin Infect Dis. 2012;55(6):877–84. doi: 10.1093/cid/cis535.
    1. Centers for Disease Control and Prevention (CDC) Achievements in public health. Reduction in perinatal transmission of HIV infection--United States, 1985-2005. MMWR Morb Mortal Wkly Rep. 2006;55(21):592–7.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir